Andrew M. Scott

Research interests

Publications

• FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy

  Nature · 2024 · https://doi.org/10.1038/s41586-024-07242-1

• Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial

  The Lancet Oncology · 2023 · https://doi.org/10.1016/s1470-2045(23)00529-6

• Radiotheranostics in oncology: current challenges and emerging opportunities

  Nature Reviews Clinical Oncology · 2022 · https://doi.org/10.1038/s41571-022-00652-y

• PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial

  The Lancet Oncology · 2022 · https://doi.org/10.1016/s1470-2045(22)00605-2

• [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

  The Lancet · 2021 · https://doi.org/10.1016/s0140-6736(21)00237-3

• [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

  The Lancet · 2021 · https://doi.org/10.1016/s0140-6736(21)00237-3

• Medical imaging and nuclear medicine: a Lancet Oncology Commission

  The Lancet Oncology · 2021 · https://doi.org/10.1016/s1470-2045(20)30751-8

• Antibody–Drug Conjugates for Cancer Therapy

  Molecules · 2020 · https://doi.org/10.3390/molecules25204764

• Bridging Bio–Nano Science and Cancer Nanomedicine

  ACS Nano · 2017 · https://doi.org/10.1021/acsnano.7b04855

• The Impact of 68Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study

  Journal of Nuclear Medicine · 2017 · https://doi.org/10.2967/jnumed.117.197160

• Persistence and Efficacy of Second Generation CAR T Cell Against the LeY Antigen in Acute Myeloid Leukemia

  Molecular Therapy · 2013 · https://doi.org/10.1038/mt.2013.154

• Comparison of ultracentrifugation, density gradient separation, and immunoaffinity capture methods for isolating human colon cancer cell line LIM1863-derived exosomes

  Methods · 2012 · https://doi.org/10.1016/j.ymeth.2012.01.002

• Monoclonal Antibodies for Cancer Therapy

  SpringerReference · 2012 · https://doi.org/10.1007/springerreference_303431

• Antibody therapy of cancer

  Nature reviews. Cancer · 2012 · https://doi.org/10.1038/nrc3236

• A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors

  Proceedings of the National Academy of Sciences · 2007 · https://doi.org/10.1073/pnas.0611693104

• Hypoxia Positron Emission Tomography Imaging With 18F-Fluoromisonidazole

  Seminars in Nuclear Medicine · 2007 · https://doi.org/10.1053/j.semnuclmed.2007.07.001

• Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans

  Proceedings of the National Academy of Sciences · 2004 · https://doi.org/10.1073/pnas.0403572101

• A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer.

  PubMed · 2003

• CLINICAL ROLE OF F-18 FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY FOR DETECTION AND MANAGEMENT OF RENAL CELL CARCINOMA

  The Journal of Urology · 2001 · https://doi.org/10.1016/s0022-5347(05)65845-4

• Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor.

  PubMed · 2001

• The contribution of 18F-fluoro-2-deoxy-glucose positron emission tomographic imaging to radiotherapy planning in lung cancer1Presented at the 13th Asia Pacific Cancer Conference, Penang, Malaysia, November 17–20, 1996 and also presented at the Royal Australasian College of Radiologists 47th Annual General and Scientific Meeting, Perth, Western Australia, October 5–9th, 1996. Accepted for presentation at the American Radium Society 79th Annual Meeting, New York, N.Y., April 30–May 4, 1997.1

  Lung Cancer · 1998 · https://doi.org/10.1016/s0169-5002(97)00086-x

• Construction and characterisation of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukaemia and lymphoma

  Molecular Immunology · 1997 · https://doi.org/10.1016/s0161-5890(97)00144-2

• The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily

  Proceedings of the National Academy of Sciences · 1997 · https://doi.org/10.1073/pnas.94.2.469

• Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer.

  Journal of Clinical Oncology · 1996 · https://doi.org/10.1200/jco.1996.14.6.1787

• Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts.

  Journal of Clinical Oncology · 1994 · https://doi.org/10.1200/jco.1994.12.6.1193

• Alzheimer's Disease, Other Dementias, Depression and Pseudo-dementia: Prevalence, Incidence and Three-Year Outcome in Liverpool

  The British Journal of Psychiatry · 1992 · https://doi.org/10.1192/bjp.161.2.230

Current projects

No projects listed.